Pharmaceutical companies are being pushed by the government to offer lower initial prices for new drugs on the understanding that the NHS will pay more if later evidence proves greater effectiveness.

The move is seen by ministers as an answer to whether patients should be allowed to “top up” NHS treatment for cancer and other medicines that Nice, the National Institute for Clinical Excellence, judges to be clinically effective but insufficiently cost-effective for the NHS to pay for.